Ian Krop, MD, PhD, is a Professor of Medicine (Medical Oncology), Associate Cancer Center Director for Clinical Research, Director of the Yale Cancer Center Clinical Trials Office, and Chief Clinical Research Officer at Yale Cancer Center. He also serves as the Chief Scientific Officer for the Translational Breast Cancer Research Consortium (TBCRC).
Dr. Krop is an international leader in the clinical care of patients with breast cancer. His research focuses on novel targeted therapies for breast cancer, particularly HER2+ breast cancer, and he was a leader in the development of the antibody-drug conjugates trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan.
Dr. Krop received his medical degree from The Johns Hopkins University School of Medicine where he also completed his PhD in Cellular and Molecular Biology. He completed his residency in Internal Medicine at Johns Hopkins Hospital, and fellowship in medical oncology at Dana-Farber/Harvard Cancer Center.
Dr. Krop cares for patients as part of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center.
Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center
35 Park Street, first fl oor
New Haven, CT 06511